OncoCyte Corporation (OCX) Announces Clinical Trial Update
OncoCyte Corporation (OCX) provided an update on its clinical development programs.
Clinical Development Highlights:
Drug Program: companies, time
Collaboration: Oncocyte
anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor & Media Contact Caroline Corner ICR Westwicke Tel: 415.202.5678
📋 Oncocyte Corporation (OCX) - Clinical Trial Update
Filing Date: 2022-08-01
Accepted: 2022-08-01 08:05:15
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
Structured Data: